LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

LLY

724.86

-2.66%↓

NVO

122.65

-0.04%↓

MRK

125.78

+0.49%↑

ABBV

166.3

+0.95%↑

TMO

544.88

+0.67%↑

HomeStock ListBristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Closed

Sector Healthcare

48.94 1.26

Overview

Share price change

24h

Current

Min

48.82

Max

49.04

Key metrics

By Trading Economics

Income

-166M

1.8B

Sales

511M

11B

P/E

Sector Avg

13.011

23.904

EPS

1.7

Dividend yield

3.565

Profit margin

15.352

Employees

34,100

EBITDA

-261M

4.9B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+12.32 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.56%

7.76%

Next Earnings

25 Apr 2024

Next Dividend date

1 May 2024

Next Ex Dividend date

5 Jul 2024

Market Stats

By TradingEconomics

Market Cap

-5.9B

98B

Previous open

47.68

Previous close

48.94

News Sentiment

By Acuity

43%

57%

92 / 278 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Bristol-Myers Squibb Co. Chart

Related News

18 Mar 2024, 10:14 UTC

Major Market Movers

2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma

13 Mar 2024, 18:16 UTC

Major Market Movers

2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy

11 Mar 2024, 22:07 UTC

Earnings
Major Market Movers

CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate

23 Feb 2024, 12:34 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares

2 Feb 2024, 12:46 UTC

Earnings

Bristol Myers Squibb 4Q Revenue Boosted by Eliquis, Opdivo

4 Apr 2024, 05:00 UTC

Top News

Big Pharma Stocks Need a Rethink. Investors Keep -2-

4 Apr 2024, 05:00 UTC

Top News

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake. -- Barrons.com

19 Mar 2024, 15:00 UTC

Acquisitions, Mergers, Takeovers

Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover -- IBD

18 Mar 2024, 12:44 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics

26 Feb 2024, 13:35 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Completes Acquisition Of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform >BMY

20 Feb 2024, 11:30 UTC

Top News

These Drug Companies Are Going Nuclear to Fight Cancer -- Heard on the Street -- WSJ

12 Feb 2024, 11:59 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

2 Feb 2024, 13:04 UTC

Earnings

Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat -- IBD

2 Feb 2024, 12:04 UTC

Earnings

Bristol-Myers Squibb Sees Total 2024 Rev to Increase by Low Single-Digits >BMY

2 Feb 2024, 12:01 UTC

Earnings

Bristol-Myers Squibb 4Q Gross Margin 76.1% >BMY

2 Feb 2024, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Rev $11.48B >BMY

2 Feb 2024, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q EPS 87c >BMY

2 Feb 2024, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Adj EPS $1.70 >BMY

2 Feb 2024, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Net $1.76B >BMY

2 Feb 2024, 09:37 UTC

Earnings

These Stocks Are Moving the Most Today: Meta, Amazon, Apple, Intel, Deckers, Skechers, Clorox, and More -- Barrons.com

31 Jan 2024, 10:14 UTC

Earnings

GSK Stock Falls After Earnings Just Miss. But Vaccine Sales Are Strong. -- Barrons.com

30 Jan 2024, 22:30 UTC

Top News

GSK Reports Earnings Wednesday. Investors Are Watching the RSV Vaccine Showdown. -- Barrons.com

30 Jan 2024, 12:10 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio: Chief Scientific Officer Philip Gregory and Chief Medical Officer Steve Bernstein Will Transition to Regeneron

30 Jan 2024, 12:10 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio Will Receive Upfront Payment of $5 M From Regeneron, a Milestone Payment for First Major Market Approval of First Approved Pdt and Royalties on Rev Generated

30 Jan 2024, 12:09 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio: Dan Lynch Will Step Down From Board in June and Will Continue in Advisory Role >TSVT

30 Jan 2024, 12:08 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio: Vicki Eatwell Will Become Chief Fincl Officer >TSVT

30 Jan 2024, 12:07 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio: About 160 Members of the Team Transitioning to Regeneron >TSVT

30 Jan 2024, 12:07 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio Reducing Remaining Workforce to Better Align With Reshaped Focus of the Co and Reduce Expenses Overall >TSVT

30 Jan 2024, 12:06 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio: Actions Follow Extensive Evaluation of Business and Strategic Alternatives by Board

30 Jan 2024, 12:06 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio to Focus Exclusively on Commercialization and Development of Abecma, BCMA-targeted CAR T Therapy for Multiple Myeloma >TSVT

Peer Comparison

Price change

Bristol-Myers Squibb Co. forecast

Price Target

By TipRanks

12.32% upside

12 Months Forecast

Average 54.25 USD  12.32%

High 65 USD

Low 40 USD

Based on 14 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

3

Buy

10

Hold

1

Sell

Technical Score

By Trading Central

48.26 / 51.2Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

92 / 278 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.